Why non-restorative sleep after MHT is often OSA, restless legs, or insomnia — and what GPs can start while waiting for a specialist.
This page summarises a CPD seminar for clinicians. It is not personal medical advice. Apply local guidelines, individualise care, and refer appropriately.
Professor Mukherjee and Dr Elliott opened with a familiar general-practice vignette: a 51-year-old woman, still in the perimenopausal window, last period about six months ago. She reports hot flushes she “takes in her stride” — but on further questioning she sticks a leg out of bed four or five times a night to cool down. That “leg sign” costs 15–30 minutes to get back to sleep; if it happens around 5 am, the night is over.
She is otherwise healthy, distressed about abdominal weight gain, and her husband has moved out of the bedroom because of his snoring — so her own sleep history is incomplete. She has morning headaches, daytime fatigue with a 4 pm nap urge while working full time, and she uses the word rage for her short temper. Bloods including thyroid and haemoglobin are normal; ferritin is 45 — “normal” on the lab slip, but clinically important later.
A three-month trial of cyclic MHT helped vasomotor symptoms and rage, but sleep remained non-restorative. At that point the speakers framed the next job: exclude an underlying sleep disorder, starting with obstructive sleep apnoea (OSA).
A key teaching point: estrogen and progesterone help stabilise the upper airway. As levels fluctuate into menopause, rates of sleep apnoea rise sharply — Professor Mukherjee cited about a 200% increase in women at menopause. Undiagnosed OSA is common, disruptive, and can drive insomnia symptoms. If usual hormone therapy has not fixed sleep, OSA should be high on the differential.
When perimenopause/menopause sleep remains poor after MHT, think OSA early — not “just hormones.”
Analogous to sex differences in cardiovascular disease presentations, women with OSA often look different from the classic male pattern:
| More typical in men | More often in women (esp. midlife) |
|---|---|
| Snoring | Fatigue |
| Observed apnoeas (often by a partner) | Insomnia / non-restorative sleep |
| Classic “loud sleeper” story | Mood disturbance |
| Morning headaches |
Many women at this age may not have a bed partner to report snoring or apnoeas. Morning headaches are asked about routinely in sleep clinic; exact pathophysiology is uncertain, but overnight hypoxia is a plausible contributor. They are typically on waking, not headaches through the whole day.
Adult OSA pathways recommend screening with validated questionnaires. Useful tools discussed included STOP-Bang, OSA-50, Berlin, and the Epworth Sleepiness Scale (to quantify sleepiness). Critical caveat: most were validated primarily in men. A low score does not rule out OSA in women — keep a low threshold for investigation when the clinical story fits.
Low questionnaire scores in women ≠ “no OSA.” Women aren’t just small men — presentation and tool performance differ.
In Australia, home sleep studies are now common and validated; for some people they are better than lab studies because the person sleeps in their own bed. Equipment can match lab sensors; the main difference is no sleep scientist watching signals in real time. Fit, active adults usually manage home studies well. Lab studies still have a role.
Apple Watch, Fitbit and similar devices are not clinical-grade for staging sleep (EEG remains gold standard). They are useful for nightly trends in the same person — most use actigraphy (movement). Lots of movement may mean OSA, restless legs, or wakefulness. If a patient says “my watch says my sleep is terrible,” take that seriously as a signal that something is disrupting sleep.
When a home study reports OSA, management depends on severity (AHI, hypoxia, arousals). While awaiting a sleep physician:
Weight-loss magnitude from a key paper cited in the talk: ~10% body-weight loss → ~30% improvement in OSA severity — a disproportionate win; smaller losses still help. GLP-1 agonists expand the toolbox. Tirzepatide (SURMOUNT programme) has TGA approval for OSA but is not PBS-listed for that indication — patients pay privately.
About 10% of people over 65 have restless legs; female predominance is roughly 2:1. Prevalence rises with age, so menopause-age women are in the window — menstrual bleeding and iron status also matter. Pathophysiology centres on brain iron and dopamine pathways.
A ferritin of 45 may be “normal” on the report but is not adequate if restless legs or frequent limb movements are present. Aim for ferritin >100; first-line is iron replacement (oral or IV as appropriate). Magnesium is not first-line.
Dopamine agonists (e.g. pramipexole) have fallen out of favour because of augmentation — roughly 10% risk per year on treatment (≈50% after 4–5 years). Prefer gabapentin or pregabalin once iron is corrected; opioids reserved for severe refractory disease. Australasian Sleep Association restless-legs guidance (discussed as forthcoming at the time of the talk) was described as moving away from dopamine agonists toward gabapentinoids.
Sleep and cognitive symptoms often appear in early perimenopause — even before the final period and sometimes before hot flushes dominate. Verbal learning/memory declines associate with poor sleep. For dementia risk messaging, the clearest link from the talk was short sleep duration <6 hours. Ask bedtime, sleep-onset time, and rise time — people often overestimate sleep by about an hour. Long sleep (>9 hours) has a weaker association and often reflects other illness (e.g. heart disease, stroke). Any cause of insufficient sleep — OSA, restless legs, insomnia — can matter because sleep clears metabolites and supports cognition.
Chronic insomnia: difficulty falling or staying asleep lasting more than three months. OSA and insomnia co-occur in about 40–50% of cases. Diagnosing one without treating the other often leaves sleep disturbed — they need different treatments.
Most effective insomnia treatment discussed: CBT-I (usually psychologist-delivered); digital CBT-I apps also exist. Watching Australia’s Sleep Revolution can help patients (and GPs) understand what CBT-I involves.
The circadian system ages: the brain responds less strongly to the main drivers — light and temperature. Practical tips from the talk: dim lights before bed; keep the bedroom cooler to help sleep onset; use bright light to support daytime alertness. Airlines already warm cabins to wake passengers and cool them to encourage sleep — the same physiology. Light therapies are not dismissed as gimmicks when used thoughtfully.
Doing questionnaires and arranging a sleep study before the specialist appointment helps shorten things for the patient.
directory.drkotha.com · Companion: menopause.drkotha.com · Theme: apricot